查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301160

醫療保健合同開發和製造機構的市場規模、份額和趨勢分析報告：2023-2030 年按服務（合同開發、合同製造）、地區和細分市場劃分的趨勢

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

醫療保健外包開發和製造機構市場的增長和趨勢

Grand View Research, Inc. 的新報告預測，到 2030 年，全球醫療保健合同開發和製造組織市場將達到 4710 億美元。

從 2023 年到 2030 年，市場預計將以 9.5% 的複合年增長率擴張。 由於研發支出的增加和外包趨勢的增加，預計該市場將出現利潤豐厚的增長。

醫療保健合同開發和製造組織 (CDMO) 在合同基礎上向各個製藥行業提供外包服務。 製藥公司外包的增加、製藥行業的擴張以及 CDMO 在降低運營和資本成本方面的幫助是預計在預測期內推動市場增長的一些關鍵因素。

此外，製藥和醫療器械公司滿足嚴格時間表的壓力越來越大，這增加了將開發和製造活動外包給 CDMO 的需求。 此外，由於新興國家對醫療器械的需求不斷增加，各公司正在將重點轉向醫療器械合同開發和製造的研發活動。 在過去的十年中，多家製藥公司轉向 CMO、CRO 和 CDMO 來幫助他們預先制定、開發和製造其新穎的創新產品。 外包是一個高增長的市場，大部分支出都集中在早期開發上。

約75%的新藥管線來自中小型生物製藥公司。 這些公司利潤豐厚，對於尋求削減成本的醫療保健提供商來說是有吸引力的目標。 因此，這些公司將服務外包給擁有專業知識和必要設備的第三方，而不是投資建設自己的基礎設施是有意義的。 一些製藥公司尋求外包服務來優化其分子開發。 例如，美國生物技術公司 Remedium Bio 於 2023 年 3 月宣布，將與比利時 CDMO Exothera 合作，擴大 Remedium 的領先基因治療候選藥物——骨關節炎藥物 AAV2-FGF18 的生產。

然而，物流成本上升、醫療機構面臨的序列化問題以及知識產權 (IP) 侵權威脅預計將在預測期內抑制醫療保健合同開發和製造組織的市場增長。

醫療保健合同開發和製造組織市場報告亮點

  • 由於製藥公司和醫療器械公司外包製造服務的增加，合同製造行業在 2022 年佔據市場主導地位，佔市場收入份額的 73.5%。
  • 在小分子合同開發子細分市場中，由於新療法的不斷增加，臨床前/細分市場預計在預測期內將以 10.4% 的最高複合年增長率增長。
  • 北美在醫療保健合同開發和製造組織市場佔據主導地位，2022 年銷售份額最大，達到 40.9%。 該地區的高份額主要是由於該地區有大量活躍的 CRO 和 CMO，尤其是在美國。
  • 預計亞太地區在預測期內將以 10.4% 的最快複合年增長率增長。 由於亞洲 CRO 和 CMO 提供的低成本合同開發和製造服務，預計該地區將出現良好的複合年增長率。

內容

第一章調查方法及範圍

  • 市場細分和範圍
    • 段定義
    • 服務
  • 區域範圍
  • 估計/預測時間表
  • 目的
  • 調查方法
  • 信息獲取
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場形成和驗證
  • 型號詳細信息
    • 產品流分析
    • 母公司市場分析
  • 輔助信息列表
  • 縮寫列表

第 2 章執行摘要

  • 市場前景
  • 分部展望
  • 競爭考慮因素

第 3 章醫療保健 CDMO 市場變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場前景
    • 相關/補充市場前景
  • 按服務分類的產品渠道分析
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 醫療保健 CDMO 市場分析工具
    • 行業分析 - 搬運工
    • PESTEL 分析
    • COVID-19 的影響分析
    • 主要交易和戰略聯盟分析

第 4 章醫療 CDMO 市場：服務評估和趨勢分析

  • 醫療保健 CDMO 市場（按服務）：細分儀表板
  • 醫療保健 CDMO 市場（按服務）：波動分析
    • 委託開發
    • 合同製造

第五章醫療 CDMO 市場：區域估算和趨勢分析

  • 2022 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美
    • 2018-2030 年市場預估和預測（收入，百萬美元）
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
    • 荷蘭
    • 比利時
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳大利亞
    • 泰國
    • 馬來西亞
    • 新西蘭
    • 新加坡
    • 菲律賓
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 智利
  • MEA
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特
    • 以色列

第 6 章競爭格局

  • 市場進入者分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2022 年公司市場份額分析
  • 公司簡介
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International

第 7 章 KoL 解釋/建議

Product Code: GVR-4-68038-438-3

Healthcare Contract Development And Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.5% from 2023 to 2030. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.

Healthcare Contract Development and Manufacturing Organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing pressure on pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in preformulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market and most spending is focused on early development.

Around 75% of new drug pipelines come from small and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce cost. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations who have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecule. For instance, in March 2023, Remedium Bio, a U.S.-based biotechnology company, entered in a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development And Manufacturing Organization Market Report Highlights

  • The contract manufacturing segment dominated the market with a revenue share of 73.5% in 2022 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies
  • By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 10.4% in the forecast period due to the rising pipeline of novel therapeutics
  • North America dominated the healthcare contract development and manufacturing organization market with the largest revenue share of 40.9% in 2022. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.
  • The Asia Pacific is projected to witness the fastest CAGR of 10.4% during the forecast period. The region is anticipated to witness a lucrative CAGR owing to the low-cost contract development and manufacturing services offered by Asian CROs and CMOs

Table of Contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Services
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Healthcare CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Product Pipeline Analysis, by Service
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies
      • 3.3.1.2. Rising Investment In R&D
      • 3.3.1.3. Growing Pharmaceutical Industry
      • 3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Compliance Issues While Outsourcing
      • 3.3.2.2. Changing Scenarios In Developing Countries
      • 3.3.2.3. Regulatory And Legal Compliance
  • 3.4. Healthcare CDMO Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat Of New Entrant
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTEL Analysis
    • 3.4.3. COVID-19 Impact Analysis
    • 3.4.4. Major Deals & Strategic Alliances Analysis
      • 3.4.4.1. Mergers & Acquisitions
      • 3.4.4.2. Geographic Expansions
      • 3.4.4.3. Partnerships
      • 3.4.4.4. Launch
      • 3.4.4.5. Collaborations

Chapter 4. Healthcare CDMO Market: Services Estimates & Trend Analysis

  • 4.1. Healthcare CDMO Market, By Services: Segment Dashboard
  • 4.2. Healthcare CDMO Market, By Services: Movement Analysis
  • 4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030
    • 4.3.1. Contract Development
      • 4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Small Molecule
      • 4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2. Preclinical
      • 4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.2. Bioanalysis and DMPK studies
      • 4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.3. Toxicology Testing
      • 4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.4. Other Preclinical Services
      • 4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3. Clinical
      • 4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.2. Phase I
      • 4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.3. Phase II
      • 4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.4. Phase III
      • 4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.5. Phase IV
      • 4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4. Laboratory Services
      • 4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.2. Bioanalytical Services
      • 4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.3. Analytical Services
      • 4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Large Molecule
      • 4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.2. Cell line development
      • 4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3. Process Development
      • 4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2. Upstream
      • 4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.2. Microbial
      • 4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.3. Mammalian
      • 4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.4. Others
      • 4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3. Downstream
      • 4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.2. MABs
      • 4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.3. Recombinant Proteins
      • 4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.4. Others
      • 4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Contract Manufacturing
      • 4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Small Molecule
      • 4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Large Molecule
      • 4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.2. MABs
      • 4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.3. Recombinant Proteins
      • 4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.4. Others
      • 4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. High Potency API
      • 4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5. Finished Dose Formulations
      • 4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.2. Solid Dose Formulation
      • 4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.3. Liquid Dose Formulation
      • 4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.4. Injectable Dose Formulation
      • 4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6. Medical Device
      • 4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.2. Class I
      • 4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.3. Class II
      • 4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.4. Class III
      • 4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Healthcare CDMO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2022 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Framework
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
    • 5.5.9. Netherlands
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Competitive Scenario
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
    • 5.5.10. Belgium
      • 5.5.10.1. Key Country Dynamics
      • 5.5.10.2. Competitive Scenario
      • 5.5.10.3. Regulatory Framework
      • 5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Framework
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. India
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.7. Malaysia
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Competitive Scenario
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.8. New Zealand
      • 5.6.8.1. Key Country Dynamics
      • 5.6.8.2. Competitive Scenario
      • 5.6.8.3. Regulatory Framework
      • 5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.9. Singapore
      • 5.6.9.1. Key Country Dynamics
      • 5.6.9.2. Competitive Scenario
      • 5.6.9.3. Regulatory Framework
      • 5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
    • 5.6.10. Philippines
      • 5.6.10.1. Key Country Dynamics
      • 5.6.10.2. Competitive Scenario
      • 5.6.10.3. Regulatory Framework
      • 5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Framework
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Mexico
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    • 5.7.4. Colombia
      • 5.7.4.1. Key Country Dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory Framework
      • 5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
    • 5.7.5. Chile
      • 5.7.5.1. Key Country Dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory Framework
      • 5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Framework
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
    • 5.8.5. Israel
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Competitive Scenario
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2022
  • 6.2. Company Profiles
    • 6.2.1. Catalent Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Lonza
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Recipharm AB
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Siegfried Holding AG
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Thermo Fisher Scientific, Inc
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Labcorp Drug Development
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Jabil Inc
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Syngene International Limited
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. IQVIA Inc.
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Almac Group
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Ajinomoto Bio-Pharma
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Service Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Adare Pharma Solutions
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Service Benchmarking
      • 6.2.12.4. Strategic Initiatives
    • 6.2.13. Alcami Corporation
      • 6.2.13.1. Company Overview
      • 6.2.13.2. Financial Performance
      • 6.2.13.3. Service Benchmarking
      • 6.2.13.4. Strategic Initiatives
    • 6.2.14. Vetter Pharma International
      • 6.2.14.1. Company Overview
      • 6.2.14.2. Financial Performance
      • 6.2.14.3. Service Benchmarking
      • 6.2.14.4. Strategic Initiatives

Chapter 7. KoL Commentary/Recommendations

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Healthcare CDMO Market, By Region 2018 - 2030 (USD Billion)
  • Table 4 Global Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 5 North America Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 6 North America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 8 Canada Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 9 Europe Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 11 UK Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 12 Germany Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 13 France Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 14 Italy Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 15 Spain Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 16 Netherlands Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 17 Belgium Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 18 Denmark Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 19 Norway Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 20 Sweden Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 21 Asia Pacific Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 22 China Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 23 Japan Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 24 India Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 25 Australia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 26 South Korea Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 27 Malaysia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 28 New Zealand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 29 Singapore Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 30 Philippines Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 31 Thailand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 32 Latin America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 33 Brazil Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 34 Mexico Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 35 Argentina Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 36 Colombia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 37 Chile Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 38 Middle East & Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 39 South Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 40 Saudi Arabia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 41 UAE Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 42 Israel Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 43 Kuwait Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Healthcare CDMO market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Healthcare CDMO Market Services outlook: Segment dashboard
  • Fig. 26 Healthcare CDMO: Services movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 29 Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 30 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
  • Fig. 31 Toxicology Testing market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Preclinical Services market, 2018 - 2030 (USD Million)
  • Fig. 33 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 34 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 35 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 36 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 37 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 38 Laboratory Services market, 2018 - 2030 (USD Million)
  • Fig. 39 Bioanalytical Services market, 2018 - 2030 (USD Million)
  • Fig. 40 Analytical Services market, 2018 - 2030 (USD Million)
  • Fig. 41 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 42 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 43 Process Development market, 2018 - 2030 (USD Million)
  • Fig. 44 Upstream market, 2018 - 2030 (USD Million)
  • Fig. 45 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 46 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 47 Others market, 2018 - 2030 (USD Million)
  • Fig. 48 Downstream market, 2018 - 2030 (USD Million)
  • Fig. 49 MABs market, 2018 - 2030 (USD Million)
  • Fig. 50 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Others market, 2018 - 2030 (USD Million)
  • Fig. 53 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 54 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 55 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 56 MABs market, 2018 - 2030 (USD Million)
  • Fig. 57 Recombinant Proteins market, 2018 - 2030 (USD Million)
  • Fig. 58 Others market, 2018 - 2030 (USD Million)
  • Fig. 59 High Potency API market, 2018 - 2030 (USD Million)
  • Fig. 60 Finished Dose Formulations market, 2018 - 2030 (USD Million)
  • Fig. 61 Solid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 62 Liquid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 63 Injectable Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 64 Medical Devices market, 2018 - 2030 (USD Million)
  • Fig. 65 Class I market, 2018 - 2030 (USD Million)
  • Fig. 66 Class II market, 2018 - 2030 (USD Million)
  • Fig. 67 Class III market, 2018 - 2030 (USD Million)
  • Fig. 68 Regional marketplace: Segment dashboard
  • Fig. 69 Regional outlook, 2022 & 2030
  • Fig. 70 North America market, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 72 Canada market, 2018 - 2030 (USD Million)
  • Fig. 73 Europe market, 2018 - 2030 (USD Million)
  • Fig. 74 Germany market, 2018 - 2030 (USD Million)
  • Fig. 75 UK market, 2018 - 2030 (USD Million)
  • Fig. 76 France market, 2018 - 2030 (USD Million)
  • Fig. 77 Italy market, 2018 - 2030 (USD Million)
  • Fig. 78 Spain market, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark market, 2018 - 2030(USD Million)
  • Fig. 80 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 81 Norway market, 2018 - 2030 (USD Million)
  • Fig. 82 Netherlands market, 2018 - 2030 (USD Million)
  • Fig. 83 Belgium market, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 85 China market, 2018 - 2030 (USD Million)
  • Fig. 86 Japan market, 2018 - 2030 (USD Million)
  • Fig. 87 India market, 2018 - 2030 (USD Million)
  • Fig. 88 Australia market, 2018 - 2030 (USD Million)
  • Fig. 89 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 90 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 91 Malaysia market, 2018 - 2030 (USD Million)
  • Fig. 92 New Zealand market, 2018 - 2030 (USD Million)
  • Fig. 93 Singapore market, 2018 - 2030 (USD Million)
  • Fig. 94 Philippines market, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 96 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 97 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 98 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 99 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 100 Chile market, 2018 - 2030 (USD Million)
  • Fig. 101 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 102 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 103 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 104 UAE market, 2018 - 2030 (USD Million)
  • Fig. 105 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 106 Israel market, 2018 - 2030 (USD Million)